Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation

Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):446-51. doi: 10.1159/000017188.


The plasma insulin-like growth factor I (IGF-I) level was determined in family members carrying the Swedish amyloid precursor protein (APP) 670/671 mutation with or without Alzheimer's disease (AD) and in age-matched controls from the same family. Plasma growth hormone (GH) and prolactin (PRL) levels were also determined. Measurement of the plasma IGF-I level by radioimmunoassay revealed a significant reduction only in the family members with AD compared to age-matched controls. However, there was no significant difference in the levels of GH and PRL between the mutation carriers with or without AD and their respective age-matched controls. These findings indicate that the mechanism(s) regulating GH and PRL were preserved and those regulating IGF-I levels might be affected in AD patients with the Swedish APP 670/671 mutation. CopyrightCopyright 1999S.KargerAG, Basel

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aging / blood
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / metabolism*
  • Female
  • Heterozygote
  • Human Growth Hormone / blood
  • Human Growth Hormone / metabolism
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Mutation / physiology*
  • Prolactin / blood
  • Radioimmunoassay
  • Sweden


  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Prolactin